Promising pre-clinical data supporting BerGenBio’s pipeline to be published and presented at upcoming leading conferences

· Bemcentinib active in pre-clinical models of IPF and NASH · IPF and cirrhotic NASH patients with aggressive disease identified by AXL blood based biomarker · BGB601 (partnered AXL ADC drug candidate) anti tumour pre-clinical data to be presented at AACR. Bergen, Norway, 13 April 2018 – BerGenBio ASA (OSE: BGBIO) announces that promising pre-clinical data demonstrating that selective AXL inhibition counteracts the progression of aggressive fibrosis in the lung and liver has been published in the international peer-reviewed journal American Journal of Respiratory and Critical Care